Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET

Company Participants

Dan Od-Cohen - Investor Relations
Adrian Rawcliffe - Chief Executive Officer
Cintia Piccina - Chief Commercial Officer
Joanna Brewer - Chief Scientific Officer
Dennis Williams - Senior Vice President, Late Stage Development
John Lunger - Chief Patient Supply Officer
Elliot Norry - Chief Medical Officer

Conference Call Participants

Marc Frahm - TD Cowen
Matthew Cowper - Leerink Partners
Paul Jeng - Guggenheim Securities
Tony Butler - Rodman & Renshaw
Graig Suvannavejh - Mizuho Securities
George Farmer - Scotiabank
Arthur He - H.C. Wainwright
Kuan-Hung Lin - Wells Fargo
Michael Kim - Zacks Small-Cap Research
Alexandre Bouilloux - Barclays

Operator

Good day and welcome to the Adaptimmune Second Quarter 2024 Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Dan Od-Cohen, Investor Relations. Please go ahead.

Dan Od-Cohen

Thank you, operator. Good morning and welcome to Adaptimmune's conference call to discuss our second quarter 2024 financial results and business updates. I would ask you to review the full text of our forward-looking statements from this morning's press release.

We anticipate making projections during this call and actual results could differ materially due to several factors including those outlined in our latest filings with the SEC. Adrian Rawcliffe, our Chief Executive Officer is here with me for the prepared portion of the call, and other members of our leadership team will be available for Q&A.

With that I'll turn the call over to Adrian Rawcliffe. Ad?

Adrian Rawcliffe

Thanks, Dan, and thanks everyone for joining us. We are incredibly proud that Adaptimmune is now a commercial stage cell therapy company. Following the US FDA approval and the launch of our first product in our sarcoma franchise, Tecelra. This is a fantastic achievement for the company for the cell therapy field and for people with synovial sarcoma.

Tecelra is the first engineered cell therapy for a solid tumor, the first medicine in its class. And it's also the first new treatment option for synovial sarcoma in over a decade and the culmination of groundbreaking R&D, our investment in manufacturing, the demonstrable clinical benefit exhibited throughout development and incredible execution of the regulatory process.